## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.85 indicates fundamental undervaluation. Quality metrics strong (ROE 31%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($61.28)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Holzer & Holzer, LLC Reminds Investors of Upcoming Lead**
- Source: GlobeNewswire | 20251209T161002 | Neutral | Relevance: 99%
-  Holzer & Holzer, LLC is reminding investors of upcoming lead plaintiff deadlines in class action lawsuits against MoonLake Immunotherapeutics (MLTX), DexCom, Inc. (DXCM), and Synopsys, Inc. (SNPS). The lawsuits allege materially false and/or misleading statements by the respective companies. Investors who purchased shares during the specified periods and suffered significant losses are encouraged to contact the firm to discuss their legal rights.

**2. Class Action by Pomerantz LLP Filed Against DexCom, Inc. – DXCM**
- Source: Fox 59 | 20251208T120906 | Neutral | Relevance: 99%
-  Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and certain officers, alleging material misstatements regarding the company's continuous glucose monitoring (CGM) systems, specifically the G6 and G7 devices. The lawsuit claims DexCom made unauthorized design changes to these devices, compromising their reliability and accuracy, leading to health risks for users. The complaint cites multiple instances where DexCom's stock price dropped following disclosures about FDA warnings, downgrades by equity researchers, and a critical report detailing "Fatal Flaws" in their products.

**3. DEXCOM, INC. (NASDAQ: DXCM) SHAREHOLDER ALERT Bernstein**
- Source: GlobeNewswire | 20251208T151654 | Neutral | Relevance: 99%
-  Bernstein Liebhard LLP reminds investors of an upcoming deadline in a securities fraud class action lawsuit against DexCom, Inc. (NASDAQ: DXCM). The lawsuit alleges that DexCom made misrepresentations regarding the accuracy and functionality of its G7 continuous glucose monitoring system. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, and suffered losses, might be eligible to join the class action.

**4. DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!**
- Source: CBS 42 | 20251207T120803 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) for alleged violations of federal securities laws. The lawsuit claims DexCom made misleading statements regarding unauthorized design changes to its G6 and G7 devices, which reportedly rendered them less reliable and posed health risks. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, are encouraged to join the lawsuit, with a deadline of December 26, 2025, to request to be appointed lead plaintiff.

**5. Pomerantz LLP Pursues Class Action Litigation Against DexCom, Inc. – DXCM**
- Source: KLAS 8 News Now | 20251207T110000 | Neutral | Relevance: 99%
-  Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and its officers, alleging that the company made false and misleading statements regarding its continuous glucose monitoring (CGM) systems, specifically the G6 and G7 models. The lawsuit claims that DexCom implemented unauthorized design changes that compromised the devices' reliability and accuracy, leading to significant health risks for users. These alleged issues resulted in multiple stock price drops following an FDA warning letter, an Oppenheimer downgrade, and a Hunterbrook report detailing "Fatal Flaws" and user hospitalizations or deaths.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |
| 2025-11-10 | Morgan Stanley | $63 | $89 | -29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |
| 2025-11-10 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 12.4% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.85 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.7B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.85 |
| Forward P/E | 26.4 |
| Current P/E | 31.8 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 84th percentile. MRS_5 at 0.6% confirms short-term momentum alignment. AM_20 at 7.0% shows strong absolute momentum above own 20MA. Outperforming sector by 8.2pp, stock-specific strength. Below SMA200 (0.88x), long-term trend not supportive. MACD histogram positive (0.89), confirming momentum. RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.86% (CS: 85) | Strong |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | 0.89 | Bullish |
| vs SMA20 | 1.070x | Above |
| vs SMA50 | 1.025x | Above |
| vs SMA200 | 0.876x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $65.62
- **Stop Loss:** $61.28 (6.6% risk)
- **Target:** $74.30 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 115
- **Position Value:** $7,546.30
- **Portfolio %:** 7.55%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*